USOR # 18109

A Prospective Observational Study to Estimate the Incidence of Febrile Neutropenia (FN) Among Subjects With Non-myeloid Malignancies at High Risk for FN and Receiving Neulasta® (pegfilgrastim) Onpro® kit or Other Physician Choice Options for Prophylaxis of FN (20170758)

• The purpose of this study is to estimate the incidence of febrile neutropenia among patients treated with chemotherapy and receiving Neulasta or Neulasta Onpro kit with every administered chemotherapy cycle, or other physician choice options for prevention of febrile neutropenia.

USOR # 18150

Treatment Resistance Following Anti-Cancer Therapies (TRANSLATE) (A9001502)

• The overall objective of this study is to better understand why tumors become resistant to treatment with standard of care (SOC) therapies that target critical aspects of tumor biology. Limited availability of post-progression tumor tissue has compromised efforts to rigorously characterize the tumor genomic and microenvironmental factors that drive resistance. Understanding mechanisms of resistance is critical to developing better anti-cancer treatments and treatment combinations. This study specifically addresses the key challenges associated with studying clinical mechanisms of resistance.